DelMar Pharmaceuticals, Inc. (DMPI) Given Consensus Recommendation of “Buy” by Analysts
DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) has been assigned an average broker rating score of 1.50 (Buy) from the four brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a hold rating and three have issued a strong buy rating on the company.
Brokers have set a 1-year consensus target price of $11.16 for the company and are predicting that the company will post ($0.15) earnings per share for the current quarter, according to Zacks. Zacks has also assigned DelMar Pharmaceuticals an industry rank of 106 out of 265 based on the ratings given to its competitors.
A number of equities research analysts recently weighed in on DMPI shares. HC Wainwright set a $12.00 price target on DelMar Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, November 29th. Maxim Group reaffirmed a “hold” rating on shares of DelMar Pharmaceuticals in a report on Monday, September 11th. Finally, Dawson James reaffirmed a “buy” rating on shares of DelMar Pharmaceuticals in a report on Tuesday, August 8th.
Several large investors have recently bought and sold shares of DMPI. Franklin Resources Inc. bought a new position in shares of DelMar Pharmaceuticals in the 2nd quarter worth $2,477,000. Sabby Management LLC bought a new position in shares of DelMar Pharmaceuticals in the 2nd quarter worth $1,484,000. Finally, Susquehanna International Group LLP bought a new position in shares of DelMar Pharmaceuticals in the 3rd quarter worth $306,000. Institutional investors and hedge funds own 16.91% of the company’s stock.
Shares of DelMar Pharmaceuticals (NASDAQ:DMPI) traded down $0.05 on Wednesday, hitting $0.88. The stock had a trading volume of 316,400 shares, compared to its average volume of 436,793. DelMar Pharmaceuticals has a fifty-two week low of $0.78 and a fifty-two week high of $5.39.
DelMar Pharmaceuticals (NASDAQ:DMPI) last released its quarterly earnings results on Monday, November 13th. The company reported ($0.18) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.01). research analysts predict that DelMar Pharmaceuticals will post -0.6 earnings per share for the current year.
DelMar Pharmaceuticals Company Profile
DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DelMar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.